L-ornithine aspartate - a rationale for its use in combination with chemotherapy, radiation, and hyperthermia in oncology.
Kleef
R
R
Scheller
A
A
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004151:Dipeptides / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*
D000970:Antineoplastic Agents; D004151:Dipeptides; C002939:ornithylaspartate